focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.21
Bid: 2.21
Ask: 2.29
Change: -0.045 (-1.96%)
Spread: 0.08 (3.62%)
Open: 2.35
High: 2.37
Low: 2.21
Prev. Close: 2.295
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

Mon, 25th Mar 2024 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug discovery and development company updates on Incanthera PLC's commercial skincare deal, announced in December 2023, with Marionnaud, part of the AS Watson Group. Says the first order from Marionnaud has now doubled to 50,000 units due to the strong demand anticipated by Marionnaud's management. The first order, on track to be delivered during the second quarter of 2024, will generate around GBP2 million in revenue for Incanthera, ImmuPharma said. ImmunPharma holds an 11% stake in Incanthera. ImmuPharma Chief Operating Officer Tim Franklin comments: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."

----------

Caspian Sunrise PLC, up 26% at 3.28p, 12-month range 2.20p-7.49p. The Kazakhstan-focused oil and gas exploration and production company said it was mulling the sale of all or part of the BNG contract area's shallow structures at "indicative prices potentially significantly greater than its current carrying value". Says any deal would likely require shareholder approval due to its size of the transaction value relative to the group. "We believe this heightened level of corporate interest in BNG's producing shallow structures is in part the result of the changes last year to the Kazakh oil trading regulations, which now require the production of oil to obtain a trading licence, and the relative scarcity of producing fields with full production licences. The sharp reduction in the discount for international sales referred to below may also have had an effect," the company says. Caspian Sunrise says no binding agreements have been entered into and there is no certainty that discussions will lead to a firm offer or that the board would put an offer before shareholders.

----------

AIM - LOSERS

----------

Aeorema Communications PLC, down 19% at 60.5p, 12-month range 55.00p-119.40p. In the six months that ended December 31, swings to pretax loss of GBP243,534 from a profit of GBP326,021 a year earlier. Revenue falls to GBP6.6 million from GBP7.1 million, while administrative expenses rise to GBP1.7 million from GBP1.2 million. Expects full-year revenue of no less than GBP19 million compared to GBP20.2 million in the financial year that ended June 30, 2023. Chair Mike Hale comments: "With a focus on adaptability and forward planning, Aeorema is well positioned for the future and is confident in its ability to deliver sustainable growth and value creation over the long term. We also expect to reaffirm our commitment to shareholders by maintaining our dividend policy. While this half year's financial performance reflects the impact of project timing, we are encouraged by the underlying strength of our business and our pipeline. Our focus remains steadfast on delivering creative brilliance for our clients on a global scale, and sustained growth and value to our shareholders."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
13 Dec 2019 12:12

ImmuPharma To List On Life Sciences Heavy Brussels Index

ImmuPharma To List On Life Sciences Heavy Brussels Index

Read more
11 Dec 2019 14:54

ImmuPharma says not looking to raise funds

(Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.

Read more
11 Dec 2019 14:03

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

Read more
28 Nov 2019 16:26

ImmuPharma shares soar as it teams up with Avion on Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced a licence and development agreement with Avion Pharmaceuticals on Thursday, for the exclusive rights to 'Lupuzor' in the United States.

Read more
28 Nov 2019 12:02

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Read more
28 Nov 2019 07:28

ImmuPharma licenses lupus drug Lupuzor to Avion in the United States

LONDON, Nov 28 (Reuters) - British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals....

Read more
30 Sep 2019 10:40

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

Read more
28 Jun 2019 12:01

Immupharma Study Demonstrates Robust Safety Profile Of Lupuzor

(Alliance News) - Immupharma PLC on Friday reported analysis of the results from the study of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, a potentially life drug

Read more
28 Jun 2019 10:27

ImmuPharma pleased with Lupuzor open-label study results

(Sharecast News) - Specialist drug discovery and development company ImmuPharma released the analysis of results from the open-label six month extension study from its original pivotal phase 3 trial of 'Lupuzor' on Friday.

Read more
26 Jun 2019 11:15

Immupharma raises ?2.66m from subscription agreement with institutional investor

(Sharecast News) - Drug discovery and development specialist Immupharma raised roughly £2.66m via a subscription agreement with institutional investor Lanstead Capital on Wednesday.

Read more
26 Jun 2019 10:14

Immupharma Raises GBP2.7 Million From Share Subscription With Lanstead

(Alliance News) - Immupharma PLC on Wednesday announced a 26.6 million share subscription to raise around GBP2.7 million at a price of 10 pence per share.The drug discovery and development

Read more
24 May 2019 11:47

Immupharma 2018 Loss Widens Amid Placing; Progresses On Pipeline

LONDON (Alliance News) - Drug development firm Immupharma PLC said Friday its 2018 loss widened amid share placing costs, whilst it continued to make "key" progress in its 2018, pretax a

Read more
7 May 2019 11:06

ImmuPharma Exploring European Listing For Combined French Businesses (ALLIPO)

LONDON (Alliance News) - ImmuPharma PLC is exploring the merger and possible separate listing of two French subsidiaries, it said Tuesday.Elro Pharma Sarl and Ureka Sarl are currently on a

Read more
1 Apr 2019 14:07

ImmuPharma Loses Exclusivity Period For Talks With Incanthera

LONDON (Alliance News) - ImmuPharma PLC on Monday said proposed partner Incanthera Ltd can now talk with other potential parties after an exclusivity period ended.In September, ImmuPharma a

Read more
14 Mar 2019 11:04

ImmuPharma struggles to convince investors in latest update

(Sharecast News) - Shares in ImmuPharma fell even further on Thursday, as the ailing drug development company struggled to give shareholders some reassurance about its future in an update.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.